协和医学杂志

2019, v.10(02) 148-151

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

晚期肾癌:治疗进展及展望
Current Status and Prospects of the Treatment of Advanced Renal Carcinoma

盛锡楠;郭军;
SHENG Xi-nan;GUO Jun;Key Laboratory of Carcinogenesis and Translational,Research Ministry of Education,Department of Renal Cancer and Melanoma,Peking University Cancer Hospital & Institute;

摘要(Abstract):

近10年来,靶向治疗在晚期肾癌治疗领域取得了快速发展,美国食品药品监督管理局先后批准了9项靶向药物用于治疗晚期肾癌,2015年底免疫检查点抑制剂用于晚期肾癌的二线治疗在临床研究中取得突破性进展,并且获得批准用于临床治疗。免疫或免疫与靶向联合治疗逐渐成为临床研究热点,本文对晚期肾癌的靶向与免疫治疗进展进行综述,并对其治疗前景进行展望。
In the past decade,the emergence of targeted therapy has provided an exciting option for the treatment of renal cell carcinoma. There were 9 targeting agents approved for the treatment of unresectable or metastatic renal carcinoma by the American Food and Drug Administration( FDA). The promise of renal carcinoma immunotherapy was officially validated in December 2015 when the FDA approved Nivoliumab for the treatment of metastatic renal carcinoma. There are an increasing number of clinical trials on immune checkpoint inhibitors alone or combined with targeting agents that are now being identified and used for renal carcinoma immunotherapy. In this review,we present a brief overview of current treatments and discuss major clinical trials and data on renal carcinoma.

关键词(KeyWords): 晚期肾癌;靶向治疗;免疫治疗;检查点抑制剂
advanced renal carcinoma;targeted therapy;immunology therapy;checkpoint inhibitor

Abstract:

Keywords:

基金项目(Foundation): 北京市医管局杨帆计划(ZYLX201603);; 北京市科学技术委员会首都临床特色应用研究(Z161100000516062)

作者(Author): 盛锡楠;郭军;
SHENG Xi-nan;GUO Jun;Key Laboratory of Carcinogenesis and Translational,Research Ministry of Education,Department of Renal Cancer and Melanoma,Peking University Cancer Hospital & Institute;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享